Breo® Ellipta®

Breo® Ellipta®

This product is manufactured by GlaxoSmithKline and is a combination of two ingredients, fluticasone furoate and vilanterol trifenatate.

This product is inhaled into the lungs using the Ellipta®.


play
Ellipta®

Why is it prescribed?

Breo® Ellipta® is used for the long term maintenance treatment of COPD in adults and is also used for the maintenance treatment of asthma in patients 18 years of age and older.

  • Breo® Ellipta® is supplied as a disposable light grey and pale blue plastic inhaler containing 2 double-foil strips, each with 30 blisters. The inhaler should be stored inside the unopened moisture- protective foil tray and only removed from the tray immediately before using for the first time. Discard the inhaler 6 weeks after opening the foil tray or when the counter reads zero (after all blisters have been used), whichever comes first.
  • Proper use of the inhaler device is key to getting the most from the medication. Have your pharmacist provide you with instructions on proper inhaler technique.
  • Use your inhaler once daily at the same time each day. Do not take more than one dose each day. Rinse your mouth thoroughly with water and spit it out after using the Breo® Ellipta®.
  • If you notice your breathing getting worse, contact your health care provider.

Alternatives

Other products that have the same ingredients as Breo® Ellipta® are •Trelegy® Ellipta® ••Trelegy® Ellipta® •

See other products used in the treatment of •allergic rhinitis •allergies •asthma •hay fever •perennial rhinitis •seasonal allergies •seasonal rhinitis •chronic bronchitis (COPD) •bronchitis •COPD •emphysema (COPD) •

COPD:
The recommended dose is one inhalation of BREO® ELLIPTA® 100/25 mcg once daily. The maximum recommended dose is one inhalation of BREO® ELLIPTA® 100/25 mcg once daily.
BREO® ELLIPTA® 200/25 mcg is not indicated for the treatment of COPD.
Asthma:
The recommended dose is one inhalation of BREO® ELLIPTA® 100/25 mcg or 200/25 mcg once-daily. The maximum recommended dose is one inhalation of BREO® ELLIPTA® 200/25 mcg once daily.


Breo® Ellipta® is a combination inhaler that contains both a long acting beta2-agonist and a corticosteroid. The long-acting beta2-agonist helps to relax the bronchial muscle making it easier for air to flow in and out of the airways. The steroid helps to reduce some of the swelling and inflammation in the lungs


Along with its benefit, Breo® Ellipta® may cause some unwanted effects. Possible side effects include:

  • upper respiratory tract infection
  • headache
  • oral candidiasis/thrush
  • itchy, runny or blocked nose
  • sinusitis
  • headache
  • voice disorders
  • cugh
  • dizziness
  • anxiety
  • tremor

  • Breo® Ellipta® should not be used by patients who have a severe allergy to milk proteins. It should also not be used by patients who have an allergy to vilanterol or fluticasone furoate.
  • Breo® Ellipta® is used for maintenance therapy and is not to be used as a rescue inhaler during an acute attack of breathing difficulties.
  • As with all long-acting beta-agonist inhalers, Breo® Ellipta® carries a warning about the risk of asthma-related death. Breo Ellipta® is not indicated for the treatment of asthma.
  • Breo® Ellipta® should not be used at higher doses than recommended and it should not be combined with other long-acting beta-agonist medications.
  • Using inhaled Breo® Ellipta® may may lead to the development of oral thrush. Patients should be instructed to rinse their mouths thoroughly after each use.
  • In clinical trials, an increased risk of developing pneumonia was noted in patients with COPD using Breo® Ellipta®. Patients and physicians should watch for signs of pneumonia development.
  • Breo® Ellipta® contains fluticasone furoate which is a corticosteroid. Steroids suppress immune function. Persons using medications that suppress immune function may be at increased risk of developing viral and bacterial infections.
  • Breo® Ellipta® may interact with other medications including the following:
    • ketoconazole
    • itraconazole
    • nefazadone
    • clarithromycin
    • beta-blockers eg. propranolol
    • medications that lower the level of potassium in your body eg.water pills
  • Always inform your pharmacist and physician of the medications you are taking.
  • Vilanterol, like other beta-agonist medications, can cause cardiovascular side effects in some patients. Due to this, Breo® Ellipta® should be used cautiously in patients with cardiovascular disorder especially coronary insufficiency, cardiac arrythmias, and hypertension.
  • Reductions in bone mineral density have eben noted in patients used inhaled steroids long term.
  • Monitor eye health. Long term use of inhaled steroids can lead to the development of glaucoma and cataracts.

Use in pregnancy: May interfere with uterine contractility. Carefully weigh benefit versus risk.  Consult with your doctor or pharmacist before use.

Use in breastfeeding: It is not known if vilanterol passes into breast milk.  Consult with your doctor or pharmacist before use.